The UTI Treatment Market Size was valued at USD 9.2 billion in 2022 and is projected to grow from USD 9.5 Billion in 2023 to USD 11.9 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.7% during the forecast period (2023 - 2032). The market driver for expanding the market is linked to the increased incidence of disorders, including diabetes and obesity in women. In addition, bladder issues and kidney stones are anticipated to fuel market expansion.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The increased prevalence of UTIs is one of the major factors propelling growth in the market for treatments for urinary tract infections. UTI incidence is rising due to changing lifestyle patterns and interactions between UTIs and other medical diseases. It is anticipated that this will increase the demand for UTI treatment services. Compared to men, women are more likely to get the condition. UTIs are a possibility for about 50% of women worldwide at least once in their lifetime. This has a sizable population and needs a lot of attention. In addition to gender, a number of additional factors contribute to the increased rate of UTIs, including obesity and diabetes. For instance, a 2020 study from the American College of Physicians and the Infectious Diseases Society of America found that UTIs account for about 6 million doctor visits annually in the US. Patients with pre-existing chronic diseases like coronary artery disease (CAD), chronic kidney disease (CKD), and diabetes mellitus (DM) had a higher risk of developing UTIs, according to a 2019 study published in the International Journal of Environmental Research and Public Health. As a result, the high prevalence of UTI leads to a demand for its treatment items, ultimately fueling market expansion. Thus, this factor is driving the market CAGR for UTI treatment.Figure 1: Percentage of urinary tract infection according to gender in different age groups
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Furthermore, hospital-acquired UTI is one of the main examples among the MDR bacteria, which is a serious concern for the infectious disease sector. New kinds of germs, commonly known as superbugs, cause infections resistant to most therapeutic options. The mortality rate of these MDR bacteria ranges from 25% to 60%. Healthcare providers all throughout the world are really concerned about this. For instance, scientists at Queen's University Belfast in Ireland have been researching the causes of superbug resistance to first-line therapy. As a result, there are now more opportunities to comprehend infectious diseases and create new treatments for them. Due to the widespread nature of this issue, significant funding is anticipated for the discovery of effective treatments. The government of Canada, the EU, and a few other wealthy nations have all made efforts to create novel treatments for microbes that are resistant to antibiotics.
However, catheters and other drainage devices are now being used by patients more frequently as a result of the increased prevalence of chronic kidney disorders, including bladder cancer and renal failure. Urinary catheter users are more likely to get complex UTIs. According to the World Health Organization (WHO), urinary catheter patients run a 5% daily risk of developing bacteriuria, and 40% get nosocomial infections. Catheter-associated urinary tract infection is believed to be caused by a number of causes, including extended catheterization, failure to get systemic antibiotic therapy, bacterial colonization of drainage bags, rapid progression of underlying illnesses, and others. Therefore, the market of UTI treatment will expand as urinary catheter use rises. Thus, it is anticipated that this aspect will accelerate UTI treatment market revenue globally.
The Market segments of UTI Treatment, based on drug class, includes quinolones, aminoglycosides, β-lactam, azoles and others. The quinolones segment held the majority share in 2022 in the UTI Treatment Market data. Many medical professionals advise patients to take quinolones to get rid of their infection swiftly. Because of their strong potency, a wide range of activity, excellent absorption, practical formulations, high serum concentrations, and relatively low frequency of adverse effects, quinolones have been chosen as antibiotics for over 50 years.
The UTI Treatment Market segmentation, based on clinical indications, includes urethritis, cystitis and pyelonephritis. The cystitis segment dominated the market growth for UTI treatment in 2022 and is projected to be the faster-growing segment during the forecast period 2022-2030. Pyelonephritis is substantially less frequent than cystitis. The recurrence of cystitis is a significant issue that affects women all over the world. Within six months of the first infection, cystitis can recur in about one-fourth of all women worldwide.
Figure 2: UTI Treatment Market, by Clinical Indications Method, 2022 & 2030 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The UTI Treatment Market data, based on end user includes hospitals and self-administered. The hospitals segment dominated the market revenue for UTI treatment in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030 because more people are getting urinary tract infections and because more people are going to the hospital for testing and treatment of their infections. In addition, patients prefer to visit hospitals since they have a qualified staff.
By region, the study provides the market insights for UTI treatment into North America, Europe, Asia-Pacific and Rest of the World. North America UTI treatment market accounted for USD 4.2 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. This can be due to several factors, including the high disease burden, significant companies' existence, infrastructure availability, rising healthcare spending, rapid technological breakthroughs, proactive government measures, and increased patient awareness.
Further, the major countries studied in the market report for UTI treatment are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: UTI TREATMENT MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Asia Pacific UTI treatment market accounts for the second-largest market share due to the high senior population and rising disease incidence rate. Growing population and the demand for affordable treatment are two variables that greatly impact market expansion. Moreover, China market of UTI treatment held the largest market share, and the India market of UTI treatment was the fastest growing market in the region.
Europe UTI treatment Market is expected to grow at the fastest CAGR from 2022 to 2030. The growth of the urinary tract infection (UTI) in the treatment market will be aided by the presence of many businesses that have made treatment simple. The construction of the health infrastructure is boosting growth overall. New product launches will also result from innovations. In Europe, there are more UTI instances. Further, the UK market of UTI treatment held the largest market share, and the Germany market of UTI treatment was the fastest growing market in the region.
UTI Treatment Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the market of UTI treatment grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the UTI treatment industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the global UTI treatment industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, UTI treatment industry has provided medicine with some of the most significant benefits. The UTI treatment market major player such as Pfizer, Cipla Inc., GlaxoSmithKline PLC, Novartis AG, Shionogi & Co. Ltd, AstraZeneca and Bayer AG.
With its headquarters in Mumbai, Cipla Limited is a worldwide pharmaceutical corporation. Cipla focuses on creating medications to treat a variety of illnesses, including arthritis, diabetes, depression, cardiovascular disease, respiratory diseases, and many others. In October 2019, Elores was purchased by Cipla from Venus Remedies Ltd. Elores is a medication used to treat infections that can be fatal and is intended to combat antibiotic resistance. The most recent Phase-3 clinical investigation revealed that Elores is superior to meropenem for the treatment of severe urinary tract infections.
Pfizer Inc. is a worldwide pharmaceutical and biotechnology company with its main office in Manhattan, New York City, on 42nd Street. Two German businessmen founded the corporation in 1849 in New York. For the fields of immunology, cancer, cardiology, endocrinology, and neurology, Pfizer develops and produces pharmaceuticals and vaccines. Each of the company's top-selling medicines or goods brings in more than $1 billion in annual sales. In July 2019, Array BioPharma Inc. was fully acquired by Pfizer Inc. When Array BioPharma joined Pfizer, it added a fantastic portfolio, including the authorised combination usage. MEKTOVI and BRAFTOVI.
Key Companies in the market of UTI treatment includes
UTI Treatment Industry Developments
October 2021: Tebipenem HBr tablets were submitted for FDA approval in a new drug application (NDA) by Spero Therapeutics Inc. for the treatment of complex urinary tract infections (cUTI), including pyelonephritis, brought on by susceptible microorganisms.
September 2021: Biapenem was introduced by BDR Pharma, one of the top generic drug makers in India, to treat patients with complex urinary tract infections, lower respiratory infections, and intra-abdominal infections.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 9.2 billion |
| Market Size 2023 | USD 9.5 billion |
| Market Size 2032 | USD 11.9 billion |
| Compound Annual Growth Rate (CAGR) | 3.7% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Drug Class, Clinical Indication, End User and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Pfizer, Cipla Inc., GlaxoSmithKline PLC, Novartis AG, Shionogi & Co. Ltd, AstraZeneca and Bayer AG |
| Key Market Opportunities | · Rising incidence of obesity |
| Key Market Dynamics | · Female anatomy · Sexual intercourse, diabetes |
Frequently Asked Questions (FAQ) :
The UTI Treatment Market size was valued at USD 9.2 Billion in 2022.
The UTI Treatment Market is projected to grow at a CAGR of 3.7% during the forecast period, 2023-2032.
North America had the largest share in the global market for UTI treatment.
The key players in the market for UTI treatment are GlaxoSmithKline PLC (UK), Abbott Laboratories (US), Seqirus (UK), Mylan NV (US), AstraZeneca (UK) and Hualan Biological Engineering Inc. (China).
The cystitis dominated the UTI treatment market in 2022.
The hospitals had the largest share in the UTI Treatment Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
